Preventing post-liver transplantation (LT) hepatic artery and portal vein thrombosis includes enoxaparin administration. Enoxaparin pharmacokinetics (PK) has not been investigated in children following LT. We described an enoxaparin PK model in 22 children the first week following LT.
Introduction
Liver transplantation (LT) is the treatment of choice for children with end-stage liver disease [1] . Vascular thrombosis remains the primary cause of early graft failure and retransplantation within the first 30 days following surgery in paediatric LT. Hepatic artery and portal vein thrombosis are reported in 5-18% of paediatric liver transplant recipients [2] [3] [4] . Various antithrombotic strategies including heparin therapy, aspirin, antithrombin (AT) concentrates and fresh frozen plasma replacement are currently used to reduce the risk of thrombotic complications, although their impact on graft survival is uncertain. No clinical guidelines are available regarding prevention [5, 6] . Prophylaxis of vascular thrombosis with low-molecular-weight heparin (LMWH), the activity of which is related to AT, might be useful. However, the efficacy of LMWH in preventing post LT hepatic artery and portal vein thrombosis has never been investigated in a paediatric population [6] [7] [8] [9] . One main issue is the optimal dosing given that subtherapeutic or supratherapeutic exposures may lead to higher risk of thrombosis or bleeding, respectively. The most commonly used LMWH in children is enoxaparin, whose dosing regimens are extrapolated from adult guidelines. Previous paediatric pharmacokinetic (PK) studies suggest that young children (< 2 months) needed higher doses of enoxaparin and multiple dose adjustments to achieve the target range of anti-Xa activity [10] [11] [12] . Enoxaparin PK has not been investigated in children following LT, although the risk of PK alteration is high as liver and renal functions, and body circulating volumes, vary after surgery. The aim of this study was to investigate enoxaparin PK along with the between-subject and unexplained variabilities in paediatric liver transplant recipients, then simulate appropriate dosing regimens.
Methods

Setting and population
This retrospective study was conducted in a 12-bed paediatric intensive care unit (PICU) of a teaching hospital in France from January 2013 to July 2015. All consecutive children aged less than 18 years who underwent an LT and received enoxaparin during the first post-operative week were included. Exclusion criteria were (i) clinical conditions where patients are unstable and enoxaparin cannot therefore be continuously administered (occurrence of death during the inclusion period, need for liver retransplantation the first week following the surgery), (ii) children who received unfractionated heparin for continuous renal replacement therapy, and (iii) unknown time of enoxaparin administration or time of blood sampling. Consent from the parent(s) of each child involved in the study was obtained before the surgery. The National Ethics Committee (Commission Nationale de l'Informatique et des Libertés, number 2132202) approved the study provided that appropriate written consent was obtained from the child's parent(s) after they were informed of the objectives of the study.
Patient management and intervention
Intravenous antibiotic prophylaxis (piperacillin-tazobactam or cefoxitin) was initiated pre-operatively. During the surgical procedure, saline fluid resuscitation and vasopressors were administered in order to achieve target preload, cardiac output and mean arterial pressure. Blood, platelets transfusion as well as fresh frozen plasma replacement were administered to reach haemoglobin levels between 7 and 10 g dl À1 and to avoid excessive bleeding. Albumin 5%, 20 ml kg À1 , was infused into the graft prior to vascular anastomosis. Whole or left split livers from deceased or living donor were transplanted according to the percentage of weight of the graft to the bodyweight of the receiver, which has to be over 1.5%. Artery, venous and portal anastomosis were performed and a biliary reconstruction was made with bilioenteric anastomotic technique (Roux en Y). Abdominal drains were placed at the time of skin closure. All children received a first dose of basiliximab after reperfusion of the graft. At the arrival in the PICU and during the following days, saline fluid resuscitation and vasopressors were pursued when appropriate. Children were extubated as soon as possible. Antibiotic prophylaxis was maintained for 48 h to 5 days, and immunosuppressive drugs included the start of tacrolimus on Day 1 post LT and a second dose of basiliximab on Day 4 post LT.
Albumin infusion replacement therapies associated with saline fluids (50/50) were given when the drain flow rate exceeded 50 ml 3 h À1 . Fresh frozen plasma replacement was administered when the drain flow rate was above 200 ml 3 h À1 .
Blood transfusions were performed if necessary to maintain the haemoglobin level between 7 and 10 g dl À1 ; platelet transfusion was performed only in case of bleeding and if the platelet count was <20 000 mm À3 . Exogenous AT was given in order to reach an AT level > 70%.
Post-operative cardiovascular, respiratory, neurologic, hepatic, renal or haematological dysfunction was defined according to the international paediatric definition of organ dysfunction [13] .
Anticoagulation protocol and assays
Enoxaparin (enoxaparine sodique, Lovenox ™ , Sanofi
Aventis, France, 0.2 ml (20 mg) = 2000 IU) was initiated 12 h after the graft hepatic artery clamping in children with a platelet count >50 000 mm À3 if there was no bleeding.
The initial dosing was 50 IU kg À1 given by subcutaneous injection every 12 h. Blood samples were drawn during routine therapeutic drug monitoring 4 h after the third injection with a target range of anti-Xa activity of 0.2-0.4 IU ml À1 . Enoxaparin dosing adjustments were empirical. When the target range was achieved, further blood samples were collected every two days. Anti-Xa activity was also measured in any of the following situations: dosing change, bleeding, need for invasive procedures or decreased hepatic arterial or portal vein velocity (estimated on Doppler ultrasound). Blood samples were collected through the central venous catheter into plastic citrated tubes and transported immediately to the laboratory at ambient temperature. After centrifugation, anti-Xa activity was measured by the chromogenic method (Biophen Heparin LRT ™ , Hyphen Biomed, Neuvillesur-Oise, France). Intra-assay-coefficient of variation was 3.6% and run-to-run coefficient of variation was 2.8%. The assay had a limit of quantification of 0.1 IU ml À1 and linearity was demonstrated over the range of 0.1-1.5 IU ml À1 .
Patient data
Demographics including preoperative bodyweight (BW PREOP ), postnatal age, sex, indication for LT, perioperative and postoperative data were recorded. Perioperative data were duration of total ischaemia, type of graft, percent of graft weight relative to receiver BW PREOP ratio, perioperative fluid administration (PFA) (ml) including saline fluid, albumin, fresh frozen plasma, blood and platelets. Postoperative data, recorded daily, included need and duration of vasopressors and mechanical ventilation, daily creatinine clearance according to the Schwartz formula [14] , daily number of organ dysfunctions, drain rate output (ml kg À1 h À1 ), urine rate output (ml kg À1 h À1 ), daily hydric balance (ml kg À1 ), daily BW (kg), haemorrhagic and thrombotic events, deep thrombocytopenia (<40 000 mm À3 ) and need for blood and/or platelets transfusions.
The following biochemical features were recorded daily: alanine amino transferase (IU l À1 ), total and indirect bilirubin levels (μmol l À1 ), gamma-glutamyltransferase (IU l À1 ), prothrombin activity (%), factor V activity (%), plasma albumin (g l À1 ), pH, plasma lactate (mmol l À1 ), AT and C-reactive protein (mg l À1 ). Results are expressed as raw numbers (%) or medians (ranges). Comparisons were performed using the Mann-Whitney and Fisher tests for continuous and categorical variables respectively.
Pharmacokinetic modelling
Enoxaparin plasma levels are related to an anti-Xa activity. Anti-Xa activity time-courses were described by a onecompartment open model with first order absorption and elimination, whose parameters were absorption rate (Ka), elimination clearance (CL) and volume of distribution (V). The bodyweight variation, BW(t), was simultaneously modelled:
where (BW PREOP + PFA) stands for the BW increase during surgery because of perioperative fluid administration, PFA, added to the preoperative BW, BW PREOP . The postoperative BW decreases during the following days, where (1 À f BW ), Hill and t BW50 are the fractional BW loss, Hill power and time to reach 50% of the BW loss. The effect of BW was taken into account according to the allometric rule [15] :
where the i and TYP subscripts denote the individual and typical parameters respectively. The PWR exponent was fixed to ¾ and 1 for CL and V terms, respectively.
Measured anti-Xa activity was analysed using a population approach, i.e. a nonlinear mixed effect modelling approach using the MONOLIX software (version 4.13s, http:// www.lixoft.com/) along with the SAEM algorithm [16] . AntiXa activities below the limit of quantification (LOQ) were coded as censored data in MONOLIX (CENS = 1), thereafter the corresponding likelihood of being below the LOQ was incorporated into the model [17] . The SAEM algorithm computed the maximum likelihood of the parameters combining all the information provided by censored and non-censored data. Differential equations were written in a MLXTRAN script file in MONOLIX to estimate the parameters. Residual variabilities were described by proportional and combined error models for anti-Xa activity and BW time-courses respectively. An exponential model was used for between-subject variabilities (BSV). The effect of a covariate on a structural parameter was retained if it caused a decrease in the Bayesian information criterion (BIC) and/or reduced the corresponding BSV with P < 0.05. Only covariates with a plausible effect on PK parameters were investigated. The main covariates of interest in this paediatric population were BW PREOP , daily BW, post-natal age, PFA, AT level, time, creatinine clearance and drain output rate.
The vector of PK parameters from 500 replicates of the database was simulated using the final model. Each vector parameter was drawn in a log-normal distribution with a variance corresponding to the previously estimated BSV. A simulated residual error was added to each simulated concentration. The 5th, 50th and 95th percentiles of the simulated dependent variables at each time point were then overlaid on the observed data and a visual inspection was performed. Because the patients received different enoxaparin regimens, the prediction-corrected visual predictive check (VPC) was used to produce the VPC plots [18] .
Diagnostic graphics were used for evaluation of the goodness-of-fit. Concentration and effects profiles were simulated and compared with the observed data with the aid of the VPC in order to validate the model.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology. org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY [19] , and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 [20] .
Results
Patient characteristics
A total of 22 children were included. LT was indicated for biliary cirrhosis for 20 children, metabolic disease and tumour for the remaining two children. Demographics, clinical and biological baselines are summarized in Table 1 . Nineteen children required perioperative vasopressor support (norepinephrine). Acute renal dysfunction was transient and resolved before the end of the inclusion period. Bleeding occurred in two children (anti-Xa activities of 0.27 IU ml À1 and <0.1 IU ml À1 , respectively) and indicated enoxaparin discontinuation (less than 36 h). No hepatic artery and/or portal vein thrombosis occurred during the study inclusion period.
None of the children had a platelet count <40 000 mm À3 during enoxaparin administration. Transient discontinuation (less than 36 h) of the treatment was indicated in four children, because of moderate bleeding in two children and the need for liver graft needle biopsy procedure in two others.
Enoxaparin dosing and anti-Xa activity
A total of 136 anti-Xa activity measurements were performed within 10-156 h after the start of enoxaparin. AntiXa activity was below 0.1 IU ml À1 in 37 samples and observed at least once in 14 (63%) children. Excluding those measurements, anti-Xa activity was at 0.18 IU ml À1 (0.1-0.92).
Among the 74 samples obtained at steady state, the target range of anti-Xa activity was reached in 23 samples (31%) (at least once in 15 children within 107 h (38-156) following the initiation of treatment), while anti-Xa activity was <0.2 IU ml À1 in 47 samples and >0.4 IU ml À1 in four samples ( Figure 1 ). All children observed at least once a subtherapeutic exposure (<0.2 IU ml À1 ) and seven (32%) remained underdosed during the whole treatment period. No significant correlation was found between anti-Xa activities and the AT levels (Spearman Rho coefficient = 0.169). Table 2 compares children who did or did not reach the anti-Xa activity range (0.2-0.4 IU ml À1 ).
Pharmacokinetic analysis
In a first step, enoxaparin pharmacokinetics was modelled without the BW effect. A one-compartment model with first order absorption and linear elimination adequately described 
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Duration of vasopressors, h (range) 5 (0-58)
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Primary liver graft dysfunction, n (%) 3 (13. Pharmacokinetics of enoxaparin in paediatric liver transplantation the data. The BW PREOP effect on CL and V improved the model, then a significant PFA positive effect was also observed on V. Then afterwards, the simultaneous modelling of enoxaparin pharmacokinetics along with BW variation, BW(t), taking into account these two effects, BW PREOP and PFA, adequately described the enoxaparin and BW timecourses. The final relationships for (i) enoxaparin CL and V were then
for an individual weighing 70 kg. Table 3 summarizes the final population estimates. All parameters were estimated with good accuracy. Figure 2 depicts population and individual predicted anti-Xa activity vs. observed anti-Xa activity. Figure 3 depicts the VPC plots which show that the observed anti-Xa activities were well centred around the simulated median predictions. Figure 4 (A and B) depicts the conditional weighted residual (CWRES) distributions over time after initiation of enoxaparin and against the predicted anti-Xa activity.
Enoxaparin dosing simulations
The objectives were to obtain anti-Xa activities between 0.2 and 0.4 IU ml À1 at 4 h post dose administration. To this end, a program based on a Bayesian approach using the final population parameters was designed to determine the next doses following a first dose of 50 IU kg À1 . The program inputs were the patient BW and PFA and the actual anti-Xa activity measured after this first dose. Also, an a priori dosing schedule, without any patient anti-Xa value, is shown for comparison. The program was run in the R program environment and the individual PK parameters were estimated via the nlm function using a Newton-type algorithm. 
Discussion
Little is known about the PK of enoxaparin in children undergoing LT. This study highlights (i) the high between-subject variability during the first week following LT, which is explained by BW and fluid administration during the surgery, (ii) and the difficulties in reaching the target range: 30% of children were underexposed during the whole PICU stay.
Using the final PK model and given the target anti-Xa activity range (0.2-0.4 IU ml À1 ), we suggest a dosing regimen taking into account these covariates. This study showed that a high proportion of children were in sub-therapeutic enoxaparin exposure during the first postoperative week, although the anti-Xa activity target range is debated. No dosing recommendations are available for the thrombosis prophylaxis in LT. The standard enoxaparin dosing regimen (50 IU kg À1 12 h À1 ) recommended for venous thromboembolism prophylaxis in children [10] seems to be insufficient given the important increase in dosing (38%) required in 86.3% of the patients to reach the target anti-Xa activity. One third of the children remained underexposed, highlighting the need to individualize the enoxaparin dosing in this population. Interestingly, a high drain outflow rate was associated with enoxaparin sub-therapeutic exposure, suggesting some loss of enoxaparin via the abdominal effluent. AT is known to be a major cofactor enhancing enoxaparin activity [21] . However, no significant correlation was found between AT level and anti-Xa activity and we were unable to assess the influence of drain outflow rate and AT level on the PK parameters, perhaps because of the small size of our population.
A one-compartment model with first order absorption and linear elimination adequately described the data and as expected the effect of BW using allometric scale on CL and V improved the model. The amount of PFA influenced the V estimate which was expected given the increase of circulating blood volume following the surgery. While the CL value was Figure 2 Population and individual predicted anti-Xa activity vs. observed anti-Xa activity Pharmacokinetics of enoxaparin in paediatric liver transplantation close to the values previously reported in children and infants, the V value was higher [12] . This may be explained by the usual subcutaneous oedema seen in our patients during the week following LT. Importantly, we simulated individualized enoxaparin dosing regimen to achieve the target range of anti-Xa activity from 0.2 to 0.4 IU ml À1 within 4 h following the administration. For the Bayesian approach, the dosing adjustment takes place on the first day from the second administration to the following ones. That could help the physician to achieve the target range from the second dose to the maintenance doses, avoiding early sub-therapeutic exposure and improving the prophylaxis of thrombosis as quickly as possible without major risk of bleeding. The a priori dosing could reach the target immediately; however, there is a greater probability to be outside the target, with a non-negligible risk of overdosing. The standardized dosing of 50 IU kg À1 12 h À1 is clearly insufficient regarding the suggested doses (more than 100 IU kg À1 12 h À1 , especially in younger children).
Our study has some limitations. In addition to the retrospective and single-centre design, the small size of the study population could limit the accuracy of the model and the identification of relevant covariates, and therefore the explanation of the high between-subject variability. Given the absence of post-LT thrombosis and the unlikely bleeding events related to enoxaparin exposure in our patients, no PK-effects relationship was identifiable. However, to the best of our knowledge, this is the first study to describe the PK of enoxaparin in this specific population. Moreover, our model could provide useful schemes of individualized enoxaparin dosing regimens (for an average patient, see Table 4 ).
In summary, enoxaparin dosing is challenging in children following LT given the high BSV related to the BW and the overload circulating volume following the surgery. The usual dosing schedule and empirical adjustments proved to be insufficient in at least 30% of patients, who never, in fact, achieved the target. Thanks to this enoxaparin model, the initial and maintenance doses could be more accurately assessed, therefore helping the physician to rapidly achieve the target range. Higher dosing regimens, especially in the youngest children, should be administered to achieve the target. Table 4 Probability of anti-Xa activity (IU ml À1 ) according to both Bayesian adjusted dosing and a priori dosing for a patient weighing 10 kg and PFA of 
